<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549182</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-51</org_study_id>
    <nct_id>NCT03549182</nct_id>
  </id_info>
  <brief_title>Serotonin, Serotonin Genetics(TPH2) and Emotion and Interference Processing</brief_title>
  <official_title>The Influence of Acute Tryptophan Depletion on Emotion and Interference Processing and Potential Moderation by 5HT Genetics (TPH2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore whether acute tryptophan depletion can affect the emotion and
      interference processing whether this effect is moderated by the TPH2 genotype
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with
      social &amp; emotional behavior, including emotional reactivity and emotion regulation, the
      present study aims to explore effects of acute tryptophan depletion (ATD) on emotion
      processing and emotional interference processing within a randomized double-blind,
      with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential
      moderating effects of the genetic makeup of the serotonin system the present study will
      include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the
      serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan
      depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT
      carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within
      subject design. To control for potential effects of pre-medication personality traits as well
      as effects of medicines on mood, subjects will be administered pre-treatment assessing
      relevant personality traits and post-treatment assessments of mood.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural processing during emotion processing as assessed via fMRI</measure>
    <time_frame>5-6h after administration of ATD, or placebo</time_frame>
    <description>Subjects will undergo a validated emotional face paradigm. To assess genotype x ATD interaction effects on neural emotional reactivity effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural processing during interference processing as assessed via fMRI</measure>
    <time_frame>5-6h after administration of ATD, or placebo</time_frame>
    <description>Subjects will undergo a validated cognitive-emotional interference paradigm. To assess genotype x ATD interaction effects on neural interference control effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural processing during the resting state as assessed via fMRI</measure>
    <time_frame>5-6h after administration of ATD, or placebo</time_frame>
    <description>Subjects will undergo a validated resting state assessment. To assess genotype x ATD interaction effects on intrinsic brain activity in the emotion and interreference related neural networks effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral interference performance</measure>
    <time_frame>5-6h after administration of ATD, or placebo</time_frame>
    <description>Subjects will undergo a emotion-cognition interference paradigm. To assess genotype x ATD interaction effects on behavioral indices of interference (congruent vs incongruent trials) behavioral performance (accuracy/reaction time) effects of ATD depletion on the corresponding behavioral indices will be compared between the TPH2 genotype groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>male TPH2-GG carriers with ATD then placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male TPH2-GG carriers with placebo then ATD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male TPH2-TTcarriers with ATD then placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male TPH2-TTcarriers with placebo then ATD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATD treatment</intervention_name>
    <description>oral administration of ATD (100g)(Acute Tryptophan Depletion)</description>
    <arm_group_label>male TPH2-GG carriers with ATD then placebo group</arm_group_label>
    <arm_group_label>male TPH2-GG carriers with placebo then ATD group</arm_group_label>
    <arm_group_label>male TPH2-TTcarriers with ATD then placebo group</arm_group_label>
    <arm_group_label>male TPH2-TTcarriers with placebo then ATD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo treatment</intervention_name>
    <description>oral administration of placebo (102.3g)</description>
    <arm_group_label>male TPH2-GG carriers with ATD then placebo group</arm_group_label>
    <arm_group_label>male TPH2-GG carriers with placebo then ATD group</arm_group_label>
    <arm_group_label>male TPH2-TTcarriers with ATD then placebo group</arm_group_label>
    <arm_group_label>male TPH2-TTcarriers with placebo then ATD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects without past or current psychiatric or neurological disorders

          -  Right-handedness

        Exclusion Criteria:

          -  History of head injury;

          -  Medical or psychiatric illness.

          -  High blood pressure, general cardio-vascular alterations

          -  History of drug or alcohol abuse or addiction.

          -  Allergy against medications or general strong allergies

          -  Sleep disorders.

          -  Visual or motor impairments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Becker, Dr.</last_name>
    <phone>86-28-61830988</phone>
    <email>ben_becker@gmx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Life Science and Technology</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihua Zhao</last_name>
      <email>zarazhao.uestc@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Benjamin Becker</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute tryptophan depletion</keyword>
  <keyword>tryptophan hydroxylase 2 gene</keyword>
  <keyword>emotion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

